UK markets closed

AERI Aug 2021 12.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.50000.0000 (0.00%)
At close: 1:49PM EDT
Full screen
Previous close3.5000
Open3.5000
Bid2.8000
Ask4.7000
Strike12.50
Expiry date2021-08-20
Day's range3.5000 - 3.5000
Contract rangeN/A
Volume4
Open interest16
  • Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase
    Business Wire

    Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase

    DURHAM, N.C., July 20, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that David A. Hollander, M.D., M.B.A., Chief Research & Development Officer presented an overview on Aerie’s globalization outlook at the Ophthalmology Innovation Summit European Innov

  • Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs
    Business Wire

    Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs

    DURHAM, N.C., July 15, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Leon J. Atencia, Director of Regulatory Affairs, reporting to Emma Beausang, Aerie’s Vice President of Regulatory Affairs. Mr. Atencia will be responsible for clinical

  • Aerie Pharmaceuticals Announces Appointment of Frank Estrada, Ed.D., as Director, Salesforce Training
    Business Wire

    Aerie Pharmaceuticals Announces Appointment of Frank Estrada, Ed.D., as Director, Salesforce Training

    DURHAM, N.C., Jun 21, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Frank Estrada, Ed.D., as Director, Salesforce Training, reporting to Evan Hockman, Aerie’s Vice President of Sales. Dr. Estrada will design, develop and implement the t